1-8 of 8
Kim Margolin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors

Victoria G. Atkinson, Jesus F. Antras, Philippe Bedard, Warren Brenner, Jacqueline Brown, Charlotte R. Lemech, Peter Lloyd, Kim Margolin, Matthen Mathew, John J. Park, Sajeve Thomas, Przemyslaw Twardowski, Humphrey Gardner, Amy Prawira, Melissa Coello, Walead Ebrahimimizadeh, Minh D. To, Rosemina Merchant, Sudhir Madduri Karanam, Arash Yavari, Lillian L. Siu, Hussein A. Tawbi, Paolo A. Ascierto
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT259.
https://doi.org/10.1158/1538-7445.AM2024-CT259
Published: 05 April 2024
View articletitled, Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors
Journal Articles

Abstract 6550: Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma

Katie M. Campbell, Zaid Bustami, Daniel G. Chen, Egmidio Medina, Cynthia R. Gonzalez, Nataly Naser Aldeen, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Jessica Maxey, Jia M. Chen, Lawrence F. Kuklinski, Kari L. Kendra, Bartosz Chmielowski, Thach-Giao Truong, Nikhil I. Khushalani, Frances Collichio, Alexandra Ikeguchi, Adrienne I. Victor, Kim Margolin, Jeffrey A. Sosman, Sapna P. Patel, Siwen Hu-Lieskovan, James Moon, Shay Bellasea, Daniel K. Wells, Christine N. Spencer, Marshall A. Thompson, Michael Wu, Philip O. Scumpia, Ari VanderWalde, Antoni Ribas
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6550.
https://doi.org/10.1158/1538-7445.AM2024-6550
Published: 22 March 2024
View articletitled, Abstract 6550: Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
Journal Articles

Abstract CT132: iPREDICT trial: A phase IIb, open label study of 89Zr-Crefmirlimab Berdoxam PET/CT in subjects with selected advanced malignancies (melanoma, merkel cell, renal cell and non-small cell lung cancers), scheduled to receive standard-of-care immunotherapy, to predict response to therapy

Kim Margolin, David Hays, Delphine L. Chen, Gary Ulaner, Ron Korn, Katherine Young, Michael Ferris, William Le, Ian Wilson
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT132.
https://doi.org/10.1158/1538-7445.AM2022-CT132
Published: 15 June 2022
View articletitled, Abstract CT132: iPREDICT trial: A phase IIb, open label study of 89Zr-Crefmirlimab Berdoxam PET/CT in subjects with selected advanced malignancies (melanoma, merkel cell, renal cell and non-small cell lung cancers), scheduled to receive standard-of-care immunotherapy, to predict response to therapy
Journal Articles

Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10

Jason John Luke, Riyue Bao, John M. Kirkwood, Yousef Zakharia, Diwakar Davar, Elizabeth Buchbinder, Theresa Medina, Adil Daud, Antoni Ribas, Jiaxin Niu, Geoffrey Gibney, Kim Margolin, Anthony J. Olszanski, Inderjit Mehmi, Takami Sato, Montaser Shaheen, Aaron Morris, Dmitri Bobilev, Katie Campbell, George Weiner, James E. Wooldridge, Arthur M. Krieg, Mohammed Milhem
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT032.
https://doi.org/10.1158/1538-7445.AM2021-CT032
Published: 01 July 2021
View articletitled, Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10
Journal Articles

Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer

Patrick A. Ott, Ramaswamy Govindan, Aung Naing, Terence W. Friedlander, Kim Margolin, Jessica J. Lin, Nina Bhardwaj, Matthew D. Hellmann, Lakshmi Srinivasan, Joel Greshock, Melissa Moles, Richard B. Gaynor, Matthew J. Goldstein, Siwen Hu-Lieskovan
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT125.
https://doi.org/10.1158/1538-7445.AM2018-CT125
Published: 01 July 2018
View articletitled, Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer
Journal Articles

Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma

Mohammed Milhem, Rene Gonzales, Theresa Medina, John M. Kirkwood, Elizabeth Buchbinder, Inderjit Mehmi, Jiaxin Niu, Montaser Shaheen, Ryan Weight, Kim Margolin, Jason Luke, Aaron Morris, David Mauro, Arthur M. Krieg, Antoni Ribas
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT144.
https://doi.org/10.1158/1538-7445.AM2018-CT144
Published: 01 July 2018
View articletitled, Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma
Journal Articles

Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

Paul Nghiem, Shailender Bhatia, Evan Lipson, Ragini Kudchadkar, Natalie Miller, Adil Daud, Steven Fling, Philip Friedlander, Harriet Kluger, Holbrook Kohrt, Lisa Lundgren, Kim Margolin, Thomas Olencki, Sunil Reddy, Erica Shantha, William Sharfman, Elad Sharon, Michi Shinohara, John Thompson, Jennifer Yearley, Suzanne Topalian, Martin Cheever
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT096.
https://doi.org/10.1158/1538-7445.AM2016-CT096
Published: 15 July 2016
View articletitled, Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma
Journal Articles

Phase I Trial of Intraperitoneal Iododeoxyuridine with and without Intravenous High-Dose Folinic Acid in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Flow Cytometric and Pharmacokinetic Analysis

Robert J. Morgan, Jr., Edward M. Newman, James H. Doroshow, Kathryn McGonigle, Kim Margolin, James Raschko, Warren Chow, George Somlo, Lucille Leong, Merry Tetef, Stephen Shibata, Victor Hamasaki, Mary Carroll, Steven Vasilev, Steven Akman, Paul Coluzzi, Lawrence Wagman, Jeff Longmate, Benjamin Paz, Yun Yen, Robert Klevecz
Journal: Cancer Research
Cancer Res (1998) 58 (13): 2793–2800.
Published: 01 July 1998
View articletitled, Phase I Trial of Intraperitoneal Iododeoxyuridine with and without Intravenous High-Dose Folinic Acid in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Flow Cytometric and Pharmacokinetic Analysis
Open the PDF for Phase I Trial of Intraperitoneal Iododeoxyuridine with and without Intravenous High-Dose Folinic Acid in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Flow Cytometric and Pharmacokinetic Analysis in another window